| Document |
Document Title |
|
JP2023502699A |
The present invention relates to pharmaceutical agents useful for the treatment and/or prevention in subjects, pharmaceutical compositions containing such compounds and their use as MCL-1 inhibitors useful for treating diseases such as c...
|
|
JP7212763B2 |
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as...
|
|
JP2023502692A |
The present invention relates to pharmaceutical agents useful for the treatment and/or prevention in subjects, pharmaceutical compositions containing such compounds and their use as MCL-1 inhibitors useful for treating diseases such as c...
|
|
JP2022552834A |
Prodrugs of myeloperoxidase (MPO) inhibitors, methods of treating MPO-related disorders (e.g., multiple system atrophy, amyotrophic lateral sclerosis, and Huntington's disease), and methods of neuroprotection, comprising prodrugs Disclos...
|
|
JP7186723B2 |
A compound of general formula ID, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.
|
|
JP2022545359A |
The present disclosure provides cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions comprising at least one such modulator, methods of treating cystic fibrosis using such modulators and phar...
|
|
JP2022545407A |
The present invention relates to macrocyclic compounds such as macrocyclic sulfonylamides. The invention further relates to related salts, solvates, prodrugs and pharmaceutical compositions, and most particularly to the use of such compo...
|
|
JP2022545400A |
The present invention relates to macrocyclic compounds such as macrocyclic sulfonylureas. The present invention further provides related salts, solvates, prodrugs and pharmaceutical compositions, as well as medical disorders and diseases...
|
|
JP2022126780A |
To provide a novel compound that has excellent tyrosine kinase inhibitory activity, or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope label, isomer or prodrug thereof.The present invention provides a c...
|
|
JP7128345B2 |
The present invention provides a compound as represented by formula (1) or a pharmaceutically acceptable salt, a solvate, an active metabolite, apolymorph, an isotope label, an isomer or a prodrug thereof. The present invention also prov...
|
|
JP2022126802A |
To provide macrocyclic molecules as modulators of the cystic fibrosis transmembrane conductance regulator.Disclosed herein are compounds of Formula (I) in the figure, and pharmaceutically acceptable salts, deuterated derivatives, and met...
|
|
JP2022537393A |
The present invention relates to pharmaceuticals useful for therapy and/or prophylaxis in a subject, pharmaceutical compositions containing such compounds and their use as MCL-1 inhibitors useful for treating diseases such as cancer. . [...
|
|
JP2022533462A |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). The compounds of the present invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV i...
|
|
JP2022524191A |
A macrocycle of formula (I) comprising a 2-carboxyindole ring is disclosed. Such compounds, and pharmaceutically acceptable salts thereof, are useful as Mcl-1 (bone marrow cell leukemia-1) inhibitors. The compound can be used in treating...
|
|
JP2022064967A |
To provide compounds, pharmaceutical compositions, and methods for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones.The substituted heterocyclic derivative com...
|
|
JP2022519764A |
Contains compounds of formulas (I) and (II), or the pharmaceutically acceptable salts described above, the compounds described herein (including pharmaceutically acceptable salts of the compounds described herein). The pharmaceutical com...
|
|
JP2022513959A |
The present invention has the formula (I) capable of regulating the activity of CFTR. [Chemical 1] (In the formula, all variables are as defined herein) with respect to the heterocyclic compound. The present invention further provides a ...
|
|
JP2022503896A |
The present invention relates to an indole macrocyclic derivative, a method for preparing the indole macrocyclic derivative, and a pharmaceutical application thereof. Specifically, the present invention relates to an indole macrocyclic d...
|
|
JPWO2020138015A1 |
The present invention is a novel compound or pharmaceutically acceptable salt thereof having anti-RSV activity and useful for the prevention or treatment of infectious diseases involving a virus of the subfamily Pneumovirus including res...
|
|
JP6914201B2 |
Inhibitors of HBV replication of Formula (I-A)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Rato Rd, and R1to R8have the meaning as defined herein.The present invention also relates to processe...
|
|
JP6888000B2 |
The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular o...
|
|
JP6832914B2 |
and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disord...
|
|
JP2021505636A |
The present invention relates to the use of NRF2 activators to treat respiratory diseases. In particular, the present invention relates to the treatment of respiratory diseases in mammals suffering from alveolar fluid retention, hypoxemi...
|
|
JP6678679B2 |
wherein R1, R2, R3, R4 and R5 are defined herein. Also provided are pharmaceutical compositions comprising the macrocyclic compound and methods for treating cancer in a patient comprising administering to the patient the macrocyclic comp...
|
|
JP2020502136A |
The present invention relates to bisarylamide analogs, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the present invention relates to the bisaryl heterocycle of formula (I). [Chemical 1]
|
|
JP2020502123A |
The present invention relates to bisaryl heterocyclic compounds, methods of producing them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the present invention relates to the bisaryl heteroc...
|
|
JP6630671B2 |
The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
|
|
JP6609258B2 |
and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or ca...
|
|
JP2019513804A |
The present disclosure describes substituted heterocyclic derivative therapeutic compounds, compositions containing the compounds, and compounds for epigenetic regulation by inhibiting bromodomain-mediated recognition of the acetyllysine...
|
|
JP6501946B2 |
A compound of general formula ID, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.
|
|
JP6501947B2 |
A compound of general formula ID, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.
|
|
JP6490713B2 |
The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and i...
|
|
JP2017532299A |
The present invention relates to a compound having the following formula (I) or a salt thereof and / or a pharmaceutically acceptable solvate thereof, and a pharmaceutical composition containing the same, especially for use as a drug, pa...
|
|
JP6111276B2 |
The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I ar...
|
|
JP6082397B2 |
The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention prov...
|
|
JP6068505B2 |
The invention relates to a compound of formula (I) wherein A, B, D and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
JP6037337B2 |
This invention relates to compounds of formula II: wherein R1, R2, ProtSH, and ProtNH are as defined, to processes for the synthesis of ecteinascidins of formula I from compounds of formula II, and to processes for the synthesis of compo...
|
|
JP2016516692A |
The present invention generally relates to compounds of formula I and includes compositions and methods for the treatment of human immunodeficiency virus (HIV) infection. The present invention provides novel inhibitors for HIV, pharmaceu...
|
|
JP5923043B2 |
The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
|
|
JP2016512558A |
Generally the present invention relates to the compound of formula I, and includes the constituent and method for the disposal of human immunodeficiency virus (HIV) infection. The present invention provides the directions for the medicin...
|
|
JP5808370B2 |
Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates t...
|
|
JP2015528484A |
The present invention relates to the compounds of formula I, their N-oxides, tautomers, prodrugs and pharmaceutically acceptable salts and their use for the manufacture of agents. In Equation I, the variables X, Y, Q1, Q2Means: X is CR3O...
|
|
JP5777562B2 |
ET743 is used in the preparation of a medicament for the treatment of the human body for cancer,
|
|
JP5739517B2 |
Compound having formula I and pharmaceutically acceptable salts or solvates thereof, their pharmaceutical formulations and use as HIV inhibitors.
|
|
JP5671453B2 |
The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R 1 , R 2 , R 33 , R 34 , m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.
|
|
JP2014534206A |
The present invention discloses compounds of formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof that inhibit RNA-containing viruses, especially hepatitis C virus (HCV). As a result, the compound of the present ...
|
|
JP5624148B2 |
Compound having formula (I), wherein -W is NH-, -N(CH3)- or piperazine, -X is a bond, -C(=O)- or S(=O)2-, -Y is C3-7alkylene, and -Z is NH-C(=O)- or -O-, and pharmaceutically acceptable salts thereof, their pharmaceutical formulations an...
|
|
JP2014051529A |
To provide a pyridazinone derivative useful as a glucan synthase inhibitor.In its many embodiments, the present invention provides: a substituted pyridazinone compound as a glucan synthase inhibitor; a method of preparing such a compound...
|
|
JP5426671B2 |
Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates t...
|
|
JP5380073B2 |
The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, ph...
|
